Page last updated: 2024-10-18

kynurenine and Neoplasms

kynurenine has been researched along with Neoplasms in 99 studies

Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
" In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases."9.01Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019)
"Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)."6.66Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020)
"In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin."6.38Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991)
" In particular, the activation of the kynurenine pathway of tryptophan degradation due to inflammation may play a key role in the development and persistence of both diseases."5.01Inflammation in cancer and depression: a starring role for the kynurenine pathway. ( Mondelli, V; Nettis, MA; Pariante, CM; Sforzini, L, 2019)
"Tryptophan metabolism is critical for cell proliferation, inflammation and immunoregulation."4.91The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. ( Becker, K; Fuchs, D; Gostner, JM; Überall, F, 2015)
"Alterations of these enzymes in cancers can shift the balance and lead to an increased production of specific byproducts that can function as oncometabolites."3.01Tryptophan and its metabolites in normal physiology and cancer etiology. ( Barnes, S; Conacci-Sorrell, M; Garcia, R; Perez-Castro, L; Venkateswaran, N, 2023)
"Upregulation of IDO1 correlates with cancer aggression, poor prognosis and shortened patient survival."3.01Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated. ( Charehjoo, A; Majidpoor, J; Mortezaee, K, 2023)
" This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizumab in Japanese patients with advanced solid tumours."2.94Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours. ( Ebata, T; Fujiwara, Y; Inatani, M; Iwasa, S; Kitano, S; Kondo, S; Koyama, T; Nakai, K; Sato, N; Shimizu, T; Shimomura, A; Tamura, K; Yamamoto, N; Yonemori, K, 2020)
"Kynurenine promotes T Reg (regulatory) differentiation, which leads to increased production of anti-inflammatory cytokines and suppression of cytotoxic activity of T cells."2.72The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. ( Ala, M, 2021)
"The development of drug resistance in tumors is a major obstacle to effective cancer chemotherapy and represents one of the most significant complications to improving long-term patient outcomes."2.72Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration. ( Feun, LG; Nguyen, DJM; Savaraj, N; Spector, SA; Theodoropoulos, G; Wangpaichitr, M; Wu, C, 2021)
"Many patients with cancer suffer from anemia, depression, and an impaired quality of life (QoL)."2.66Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer. ( Egger, EM; Fuchs, D; Kink, P; Kurz, K; Lanser, L; Weiss, G; Willenbacher, W, 2020)
"Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)-programmed death-ligand 1 signaling pathways."2.61Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis. ( Bao, R; Labadie, BW; Luke, JJ, 2019)
"However, without Trp, tumors cannot achieve an immune escape through either enzyme."2.58Targeting tryptophan availability to tumors: the answer to immune escape? ( Badawy, AA, 2018)
"A series of human cancers over-express IDO1 in a constitutive way."2.55IDO1: An important immunotherapy target in cancer treatment. ( Li, F; Li, S; Liu, J; Zhang, R, 2017)
"In the field of psychiatric disorders, namely in schizophrenia and depression, the role of IDO is linked to immune dysregulation."2.52[Indoleamine 2,3-dioxygenase in oncology and psychiatry]. ( Horáček, J; Vonka, V, 2015)
"IDO can be expressed by tumors themselves, but, in addition, its natural site of expression is the host immune cells recruited by the tumor (particularly dendritic cells and macrophages)."2.48Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. ( Johnson, TS; Munn, DH, 2012)
"In these symptoms, AIDS resembles classical pellagra due to dietary deficiency of Trp and niacin."2.38Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. ( Borden, EC; Brown, RR; Datta, SP; Malone, DG; Ozaki, Y; Sondel, PM, 1991)
"Malignant tumors often escape anticancer immune surveillance by suppressing the cytotoxic functions of T lymphocytes."1.91L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes. ( Abooali, M; Berger, SM; Cholewa, D; Fasler-Kan, E; Gibbs, BF; Klenova, E; Lall, GS; Milošević, M; Ruggiero, S; Schlichtner, S; Sumbayev, VV; Yasinska, IM, 2023)
"Tumors are heterogeneous cellular environments with entwined metabolic dependencies."1.72A pan-cancer metabolic atlas of the tumor microenvironment. ( Baruah, P; Ghoshdastider, U; Kulshrestha, T; Rohatgi, N; Skanderup, AJ, 2022)
"Discovery of novel strategies for cancer immunotherapy including natural small molecules is needed."1.72Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. ( Cao, Z; Chen, C; Chen, G; Huang, J; Huang, M; Lei, H; Lu, Y; Ma, Y; Song, Y; Wu, F; Zhang, C; Zhang, L; Zhao, Y; Zhou, J, 2022)
"Multidrug resistant cancer cells are hard to eradicate for the inefficacy of conventional anticancer drugs."1.42An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells. ( Buondonno, I; Campia, I; Castella, B; Gazzano, E; Ghigo, D; Kopecka, J; Riganti, C; Rolando, B, 2015)
"A total of 971 incident cancer cases (507 men and 464 women) were identified over a median follow-up time of 12 years."1.40Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study. ( Eussen, SJ; Meyer, K; Midttun, Ø; Nygård, O; Tell, GS; Ueland, PM; Ulvik, A; Vollset, SE; Zuo, H, 2014)
"Malignant tumors arise, in part, because the immune system does not adequately recognize and destroy them."1.36Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. ( Bowman, KJ; Burn, TC; Combs, AP; Fridman, JS; Haley, PJ; Hansbury, MJ; Koblish, HK; Neilan, CL; Scherle, PA; Sparks, RB; Vaddi, K; Waeltz, P; Yang, G; Yue, EW, 2010)
"If bladder cancer is caused by agents present in the urine, as is widely believed, this mechanism may also protect against carcinogenesis."1.27Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis. ( Anderson, K; Kaufman, JE; Parsons, CL, 1987)

Research

Studies (99)

TimeframeStudies, this research(%)All Research%
pre-199016 (16.16)18.7374
1990's1 (1.01)18.2507
2000's6 (6.06)29.6817
2010's35 (35.35)24.3611
2020's41 (41.41)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L2
Hitosugi, T1
Zhang, L3
Zhang, S2
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y2
Mao, H1
Chen, PR1
Wang, D2
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J2
Yang, C1
Ng, CT1
Li, D1
Perez-Castro, L1
Garcia, R1
Venkateswaran, N1
Barnes, S1
Conacci-Sorrell, M1
Watson, MJ1
Delgoffe, GM1
Peyraud, F1
Guegan, JP1
Bodet, D1
Cousin, S1
Bessede, A1
Italiano, A1
Fiore, A1
Zeitler, L2
Russier, M1
Groß, A1
Hiller, MK1
Parker, JL1
Stier, L1
Köcher, T1
Newstead, S1
Murray, PJ2
Rohatgi, N1
Ghoshdastider, U1
Baruah, P1
Kulshrestha, T1
Skanderup, AJ1
McGovern, K3
Castro, AC2
Cavanaugh, J2
Coma, S2
Walsh, M1
Tchaicha, J2
Syed, S1
Natarajan, P1
Manfredi, M2
Zhang, XM2
Ecsedy, J1
Wang, LT1
Liu, KY1
Wang, SN1
Lin, MH1
Liao, YM1
Lin, PC1
Huang, SK1
Hsu, SH1
Chiou, SS1
Zhang, Y3
Hu, Z1
Zhang, J1
Ren, C1
Wang, Y1
Chen, G1
Huang, J1
Lei, H1
Wu, F1
Chen, C1
Song, Y1
Cao, Z1
Zhang, C2
Ma, Y1
Huang, M1
Zhou, J1
Lu, Y1
Zhao, Y1
Cui, J1
Tian, Y1
Liu, T2
Lin, X1
Li, L2
Li, Z1
Shen, L1
Powderly, JD1
Klempner, SJ1
Naing, A1
Bendell, J1
Garrido-Laguna, I1
Catenacci, DVT1
Taylor, MH1
Lee, JJ1
Zheng, F1
Zhou, F1
Gong, X1
Gowda, H1
Beatty, GL1
Zhou, H1
Wen, H1
Wang, L1
Xu, M1
Jia, Y1
Duan, S1
Di, B1
Yu, Z1
Hu, C1
Charehjoo, A1
Majidpoor, J1
Mortezaee, K1
Azimnasab-Sorkhabi, P1
Soltani-Asl, M1
Yoshinaga, TT1
Zaidan Dagli, ML1
Massoco, CO1
Kfoury Junior, JR1
Xue, C1
Li, G1
Zheng, Q1
Gu, X1
Shi, Q1
Su, Y1
Chu, Q1
Yuan, X1
Bao, Z1
Lu, J2
Schlichtner, S1
Yasinska, IM1
Klenova, E1
Abooali, M1
Lall, GS1
Berger, SM1
Ruggiero, S1
Cholewa, D1
Milošević, M1
Gibbs, BF1
Fasler-Kan, E1
Sumbayev, VV1
Kim, HJ1
Moon, JH1
Chung, SW1
Abraham, I1
Park, J1
Nah, Y1
Kim, WJ1
Wu, D1
Zhou, Y1
Fu, H1
Huang, Q1
Qin, G1
Lv, J2
Lai, S1
Zhang, H2
Tang, K2
Ma, J2
Fiskesund, R1
Zhang, X1
Huang, B2
Holthuijsen, DDB1
van Roekel, EH1
Bours, MJL1
Ueland, PM3
Breukink, SO1
Janssen-Heijnen, MLG1
Keulen, ETP1
Gsur, A1
Kok, DE1
Ulvik, A3
Weijenberg, MP1
Eussen, SJPM1
Günther, J1
Däbritz, J1
Wirthgen, E2
Thomas, S1
Laury-Kleintop, L1
Prendergast, GC1
Zhai, L1
Ladomersky, E1
Bell, A1
Dussold, C1
Cardoza, K1
Qian, J1
Lauing, KL1
Wainwright, DA2
Klar, R1
Michel, S1
Schell, M1
Hinterwimmer, L1
Zippelius, A1
Jaschinski, F1
Opitz, CA1
Somarribas Patterson, LF1
Mohapatra, SR1
Dewi, DL1
Sadik, A1
Platten, M2
Trump, S1
Sadok, I1
Tyszczuk-Rotko, K1
Mroczka, R1
Staniszewska, M1
Hua, S1
Chen, F1
Wang, X1
Gou, S1
Riess, C1
Schneider, B1
Kehnscherper, H1
Gesche, J1
Irmscher, N1
Shokraie, F1
Classen, CF1
Domanska, G1
Zimpfer, A1
Strüder, D1
Junghanss, C1
Maletzki, C1
Lanser, L1
Kink, P1
Egger, EM1
Willenbacher, W1
Fuchs, D4
Weiss, G2
Kurz, K1
Park, SY1
Nam, JS1
Jiang, S1
Li, H3
Piao, L1
Jin, Z1
Liu, J2
Chen, S1
Liu, LL1
Shao, Y1
Zhong, S1
Wu, B1
Li, W1
Ren, J1
Wang, H1
Jin, R1
Heinsberg, LW1
Lockwood, MB1
Jang, MK1
Doorenbos, AZ1
Campesato, LF1
Budhu, S1
Weng, CH1
Gigoux, M1
Cohen, IJ1
Redmond, D1
Mangarin, L1
Pourpe, S1
Liu, C1
Zappasodi, R1
Zamarin, D1
Manfredi, MG1
Merghoub, T1
Wolchok, JD1
Boros, F1
Vécsei, L1
Le Naour, J1
Galluzzi, L1
Zitvogel, L1
Kroemer, G1
Vacchelli, E1
Heidari, F1
Ramezani, A1
Erfani, N1
Razmkhah, M1
Liu, XH1
Zhai, XY1
Ala, M1
Kim, M1
Tomek, P1
Matsuda, A1
Hata, A1
Tanaka, A1
Matsuda, H1
Wangpaichitr, M1
Theodoropoulos, G1
Nguyen, DJM1
Wu, C1
Spector, SA1
Feun, LG1
Savaraj, N1
Li, F1
Zhang, R1
Li, S1
Liu, Y1
Liang, X1
Yin, X1
Ji, T1
Dong, W1
Jin, X1
Chen, D1
Xie, HQ1
Zhao, B1
Zhao, T1
Hu, ZW1
Cao, X1
Qin, FX1
Ait-Belkacem, R2
Bol, V1
Hamm, G1
Schramme, F1
Van Den Eynde, B1
Poncelet, L2
Pamelard, F1
Stauber, J2
Gomes, B2
Schäuble, S1
Stavrum, AK1
Bockwoldt, M1
Puntervoll, P1
Heiland, I1
Cervenka, I1
Agudelo, LZ1
Ruas, JL1
Cheong, JE1
Sun, L1
Badawy, AA1
Triplett, TA1
Garrison, KC1
Marshall, N1
Donkor, M1
Blazeck, J1
Lamb, C1
Qerqez, A1
Dekker, JD1
Tanno, Y1
Lu, WC1
Karamitros, CS1
Ford, K1
Tan, B1
Kumada, Y1
Yamany, MS1
Sentandreu, E1
Fromm, G1
Tiziani, S1
Schreiber, TH1
Ehrlich, LIR1
Stone, E1
Georgiou, G1
Wang, W1
Zhuang, X1
Liu, W1
Dong, L1
Sun, H1
Du, G1
Ye, L1
Labadie, BW1
Bao, R1
Luke, JJ1
Cronin, SJF1
Seehus, C1
Weidinger, A1
Talbot, S1
Reissig, S1
Seifert, M1
Pierson, Y1
McNeill, E1
Longhi, MS1
Turnes, BL1
Kreslavsky, T1
Kogler, M1
Hoffmann, D1
Ticevic, M1
da Luz Scheffer, D1
Tortola, L1
Cikes, D1
Jais, A1
Rangachari, M1
Rao, S1
Paolino, M1
Novatchkova, M1
Aichinger, M1
Barrett, L1
Latremoliere, A1
Wirnsberger, G1
Lametschwandtner, G1
Busslinger, M1
Zicha, S1
Latini, A1
Robson, SC1
Waisman, A1
Andrews, N1
Costigan, M1
Channon, KM1
Kozlov, AV1
Tebbe, M1
Johnsson, K1
Woolf, CJ1
Penninger, JM1
Sforzini, L1
Nettis, MA1
Mondelli, V1
Pariante, CM1
Marillier, R1
Zimmer, P1
Joisten, N1
Schenk, A1
Bloch, W1
Ning, S1
Ghandi, M1
Kryukov, GV1
Gopal, S1
Deik, A1
Souza, A1
Pierce, K1
Keskula, P1
Hernandez, D1
Ann, J1
Shkoza, D1
Apfel, V1
Zou, Y1
Vazquez, F1
Barretina, J1
Pagliarini, RA1
Galli, GG1
Root, DE1
Hahn, WC1
Tsherniak, A1
Giannakis, M1
Schreiber, SL1
Clish, CB1
Garraway, LA1
Sellers, WR1
Ebata, T1
Shimizu, T1
Fujiwara, Y1
Tamura, K1
Kondo, S1
Iwasa, S1
Yonemori, K1
Shimomura, A1
Kitano, S1
Koyama, T1
Sato, N1
Nakai, K1
Inatani, M1
Yamamoto, N1
Wick, W1
Opitz, C1
Zuo, H2
Tell, GS2
Vollset, SE2
Nygård, O2
Midttun, Ø2
Meyer, K2
Eussen, SJ2
Gostner, JM1
Becker, K1
Überall, F1
Campia, I1
Buondonno, I1
Castella, B1
Rolando, B1
Kopecka, J1
Gazzano, E1
Ghigo, D1
Riganti, C1
Vonka, V1
Horáček, J1
Yeung, AW1
Terentis, AC1
King, NJ1
Thomas, SR1
Weinmann, H1
Bostian, AC1
Eoff, RL1
Karami, P1
Majidi, MR1
Johari-Ahar, M1
Barar, J1
Omidi, Y1
Shi, JG1
Bowman, KJ2
Chen, X1
Maleski, J1
Leopold, L1
Yeleswaram, S1
Macchiarulo, A1
Camaioni, E1
Nuti, R1
Pellicciari, R1
Costantino, G1
Koblish, HK1
Hansbury, MJ1
Yang, G1
Neilan, CL1
Haley, PJ1
Burn, TC1
Waeltz, P1
Sparks, RB1
Yue, EW1
Combs, AP1
Scherle, PA1
Vaddi, K1
Fridman, JS1
Munn, DH2
Garber, K1
Harden, JL1
Egilmez, NK1
Johnson, TS1
SPACEK, M1
QUAGLIARIELLO, E1
AURICCHIO, S1
CASALE, M1
TANCREDI, F1
LEPPANEN, VV1
OKA, M1
NAIK, VR1
BHIDE, SV1
TAKATORI, K1
ISHIGURO, I1
ASANO, S1
KUZUYA, H1
OKAMOTO, M1
KONO, R1
MORISHIMA, K1
SHIBA, S1
TERAWAKI, A1
MIYATAKE, M1
PERISSINOTTO, B1
BENASSI, CA1
ALLEGRI, G1
BRYAN, GT1
BROWN, RR4
PRICE, JM1
KHALAFALLAH, AS1
ABUL-FADL, MA1
HAGGERTY, JF1
SULLIVAN, MX1
Schröcksnadel, K1
Wirleitner, B1
Winkler, C2
Schroecksnadel, K1
Fiegl, M1
Prassl, K1
Denz, HA1
Khan, JA1
Forouhar, F1
Tao, X1
Tong, L1
Zamanakou, M1
Germenis, AE1
Karanikas, V1
Ogasawara, K1
Nakamura, Y1
Nakamura, J1
Yokoyama, K1
Ozaki, Y1
Datta, SP1
Borden, EC2
Sondel, PM2
Malone, DG1
Kaufman, JE1
Anderson, K1
Parsons, CL1
Lee, CM2
Kohler, PC1
Hank, JA1
Storer, BE1
Byrne, GI1
Lehmann, LK1
Kirschbaum, JG1
Coon, WW1
Nagler, E1
Cozzolino, G1
Scianaro, L1
Dominici, G1
Milia, U1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)[NCT03085914]Phase 1/Phase 270 participants (Actual)Interventional2017-05-02Completed
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878]20 participants (Anticipated)Interventional2023-07-10Enrolling by invitation
The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure[NCT02967419]60 participants (Anticipated)Observational2017-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)

A DLT was defined as the occurrence of any of the protocol-specified toxicities occurring up to and including Day 28 for the cohorts where mFOLFOX6 and nab-paclitaxel/gemcitabine are administered and Day 21 for all other chemotherapy regimens in Phase 1, except those with a clear alternative explanation (eg, disease progression) or transient (≤ 72 hours) abnormal laboratory values without associated clinically significant signs or symptoms based on investigator determination. (NCT03085914)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Group A: Epa + Pembrolizumab + mFOLFOX62
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine0
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin0
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent0
Group E: Epa + Pembrolizumab + Cyclophosphamide0
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent3
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent0

Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of epacadostat, pembrolizumab, or chemotherapy. Serious adverse event is defined as an event that meets 1 of the following criteria: is fatal or life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or a substantial disruption of a person's ability to conduct normal life functions, constitutes a congenital anomaly or birth defect,is a medically important event that may jeopardize the participant or may require medical or surgical intervention to prevent 1 of the outcomes listed above. (NCT03085914)
Timeframe: Up to 21 months

,,,,,,
InterventionParticipants (Count of Participants)
TEAESerious TEAE
Group A: Epa + Pembrolizumab + mFOLFOX695
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine95
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin113
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent96
Group E: Epa + Pembrolizumab + Cyclophosphamide134
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent86
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent115

Phases 1 and 2: Objective Response Rate (ORR)

ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. (NCT03085914)
Timeframe: Up to Week 18

,,,,,,
InterventionParticipants (Count of Participants)
Complete ResponsePartial Response
Group A: Epa + Pembrolizumab + mFOLFOX605
Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine12
Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin03
Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent02
Group E: Epa + Pembrolizumab + Cyclophosphamide03
Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent01
Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent05

Reviews

40 reviews available for kynurenine and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Gene Expression Regulation, Enzymologic; Huma

2021
Tryptophan and its metabolites in normal physiology and cancer etiology.
    The FEBS journal, 2023, Volume: 290, Issue:1

    Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptophan; Tryp

2023
Fighting in a wasteland: deleterious metabolites and antitumor immunity.
    The Journal of clinical investigation, 2022, 01-18, Volume: 132, Issue:2

    Topics: Adenosine; Animals; Humans; Immunotherapy; Kynurenine; Lactic Acid; Neoplasms; Reactive Oxygen Speci

2022
Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine;

2022
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm

2022
Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
    International immunopharmacology, 2023, Volume: 118

    Topics: Ecosystem; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Mi

2023
IL4i1 and IDO1: Oxidases that control a tryptophan metabolic nexus in cancer.
    The Journal of biological chemistry, 2023, Volume: 299, Issue:6

    Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidoreductases; Tryptophan; Tu

2023
Indoleamine-2,3 dioxygenase: a fate-changer of the tumor microenvironment.
    Molecular biology reports, 2023, Volume: 50, Issue:7

    Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan; Tumor Microenvironm

2023
Tryptophan metabolism in health and disease.
    Cell metabolism, 2023, 08-08, Volume: 35, Issue:8

    Topics: Dioxygenases; Humans; Kynurenine; Neoplasms; Tryptophan

2023
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment.
    Frontiers in immunology, 2019, Volume: 10

    Topics: Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm

2019
The therapeutic potential of targeting tryptophan catabolism in cancer.
    British journal of cancer, 2020, Volume: 122, Issue:1

    Topics: Animals; Enzyme Inhibitors; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine;

2020
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Anemia; Animals; Depression; Fatigue; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Ky

2020
Systematic Review of the Kynurenine Pathway and Psychoneurological Symptoms Among Adult Cancer Survivors.
    Biological research for nursing, 2020, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cancer Survivors; Female; Humans; Kynurenic Acid; Kynure

2020
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs.
    Expert opinion on investigational drugs, 2020, Volume: 29, Issue:11

    Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Drug Development; Humans; Kynurenine; Neoplasms

2020
Trial watch: IDO inhibitors in cancer therapy.
    Oncoimmunology, 2020, 06-14, Volume: 9, Issue:1

    Topics: Animals; Enzyme Inhibitors; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Tryptophan

2020
Indoleamine 2, 3-Dioxygenase: A Professional Immunomodulator and Its Potential Functions in Immune Related Diseases.
    International reviews of immunology, 2022, Volume: 41, Issue:3

    Topics: Adjuvants, Immunologic; Humans; Immune System Diseases; Immunologic Factors; Indoleamine-Pyrrole 2,3

2022
Role of tryptophan metabolism in cancers and therapeutic implications.
    Biochimie, 2021, Volume: 182

    Topics: Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasm Proteins; Neopl

2021
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy.
    European journal of pharmacology, 2021, Apr-05, Volume: 896

    Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn

2021
Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Enzyme Inhibitors; Humans; Immunotherapy; Indolea

2021
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
    International journal of molecular sciences, 2021, Jul-09, Volume: 22, Issue:14

    Topics: Cisplatin; Drug Resistance, Neoplasm; Energy Metabolism; Glycolysis; Humans; Kynurenine; Mitochondri

2021
IDO1: An important immunotherapy target in cancer treatment.
    International immunopharmacology, 2017, Volume: 47

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Immu

2017
Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health.
    Science (New York, N.Y.), 2017, Jul-28, Volume: 357, Issue:6349

    Topics: Brain; Depression; Exercise; Gastrointestinal Microbiome; Gastrointestinal Tract; Humans; Inflammati

2017
Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Trends in pharmacological sciences, 2018, Volume: 39, Issue:3

    Topics: Animals; Antineoplastic Agents; Humans; Immunosuppressive Agents; Immunotherapy; Indoleamine-Pyrrole

2018
Targeting tryptophan availability to tumors: the answer to immune escape?
    Immunology and cell biology, 2018, Volume: 96, Issue:10

    Topics: Albumins; Animals; Biomarkers; Fatty Acids; Humans; Kynurenine; Metabolic Networks and Pathways; Mol

2018
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-01, Volume: 25, Issue:5

    Topics: Cell Line, Tumor; Computational Biology; Enzyme Inhibitors; Gene Expression Profiling; Humans; Immun

2019
Inflammation in cancer and depression: a starring role for the kynurenine pathway.
    Psychopharmacology, 2019, Volume: 236, Issue:10

    Topics: Antidepressive Agents; Depression; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infl

2019
[Immune modulation by tryptophan metabolism: relevance for autoimmune and tumor diseases].
    Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:28-29

    Topics: Animals; Autoimmune Diseases; Brain; Dietary Supplements; Disease Models, Animal; Dose-Response Rela

2013
The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
    Expert opinion on therapeutic targets, 2015, Volume: 19, Issue:5

    Topics: Animals; Cell Proliferation; Dendritic Cells; Humans; Immunity, Cellular; Immunotherapy; Indoleamine

2015
[Indoleamine 2,3-dioxygenase in oncology and psychiatry].
    Casopis lekaru ceskych, 2015, Volume: 154, Issue:1

    Topics: Brain; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interferon-gamma; Kynurenine; Mental Disorders;

2015
Role of indoleamine 2,3-dioxygenase in health and disease.
    Clinical science (London, England : 1979), 2015, Volume: 129, Issue:7

    Topics: Animals; Bacterial Infections; Catalysis; Gene Expression Regulation, Enzymologic; Humans; Indoleami

2015
Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.
    ChemMedChem, 2016, Mar-04, Volume: 11, Issue:5

    Topics: Adenosine; Humans; Immunotherapy; Kynurenine; Neoplasms; Protein Serine-Threonine Kinases; Receptor,

2016
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease.
    Amino acids, 2009, Volume: 37, Issue:2

    Topics: Animals; Crystallography, X-Ray; Enzyme Activation; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2

2009
New promises for manipulation of kynurenine pathway in cancer and neurological diseases.
    Expert opinion on therapeutic targets, 2009, Volume: 13, Issue:2

    Topics: Animals; Drug Delivery Systems; Drug Discovery; Humans; Huntington Disease; Indoleamine-Pyrrole 2,3,

2009
Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.
    Immunological investigations, 2012, Volume: 41, Issue:6-7

    Topics: Animals; Autoimmunity; Cell Lineage; Dendritic Cells; Gene Expression Regulation; Humans; Immune Tol

2012
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.
    Immunological investigations, 2012, Volume: 41, Issue:6-7

    Topics: Animals; Antineoplastic Agents; Dendritic Cells; Enzyme Inhibitors; Humans; Immune Tolerance; Indole

2012
Monitoring tryptophan metabolism in chronic immune activation.
    Clinica chimica acta; international journal of clinical chemistry, 2006, Volume: 364, Issue:1-2

    Topics: Autoimmune Diseases; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infections; Kynurenine; Neoplasms

2006
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
    Expert opinion on therapeutic targets, 2007, Volume: 11, Issue:5

    Topics: Acrylamides; Adenosine Diphosphate Ribose; Aging; Animals; Antineoplastic Agents; Autoimmune Disease

2007
Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
    Immunology letters, 2007, Aug-15, Volume: 111, Issue:2

    Topics: Animals; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; T-Lymphocytes; Tryptop

2007
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
    Advances in experimental medicine and biology, 1991, Volume: 294

    Topics: Acquired Immunodeficiency Syndrome; Autoimmune Diseases; Enzyme Induction; Female; Humans; Indoleami

1991

Trials

3 trials available for kynurenine and Neoplasms

ArticleYear
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
    The oncologist, 2022, 11-03, Volume: 27, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Kynurenine; Neoplasms; Programmed Cell Death

2022
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
    Investigational new drugs, 2020, Volume: 38, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl

2020
Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:6

    Topics: Adult; Aged; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Male; Middle Aged; Mo

2017

Other Studies

56 other studies available for kynurenine and Neoplasms

ArticleYear
Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling.
    Molecular cell, 2022, 03-03, Volume: 82, Issue:5

    Topics: Amino Acid Transport System y+; Ferroptosis; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenin

2022
A pan-cancer metabolic atlas of the tumor microenvironment.
    Cell reports, 2022, 05-10, Volume: 39, Issue:6

    Topics: Cell Line, Tumor; Humans; Kynurenine; Neoplasms; Stromal Cells; Tryptophan Oxygenase; Tumor Microenv

2022
Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression.
    Molecular cancer therapeutics, 2022, 08-02, Volume: 21, Issue:8

    Topics: Animals; Cytochrome P-450 CYP1A1; Cytokines; Humans; Immunosuppression Therapy; Kynurenine; Mice; Ne

2022
Aryl hydrocarbon receptor-kynurenine axis promotes oncogenic activity in BCP-ALL.
    Cell biology and toxicology, 2023, Volume: 39, Issue:4

    Topics: Animals; Humans; Kynurenine; Mice; Neoplasms; Polycyclic Aromatic Hydrocarbons; Receptors, Aryl Hydr

2023
Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Animals; Cell Line, Tumor; Flavones; Immunotherapy; Kynurenine; Mice; Neoplasms; Programmed Cell Dea

2022
Pancancer Analysis of Revealed
    Disease markers, 2022, Volume: 2022

    Topics: B7 Antigens; Biomarkers, Tumor; DNA; Humans; Immunotherapy; Kynurenine; Methyltransferases; Microsat

2022
Label-free tumor cell screening based on IDO1-mediated tryptophan metabolism at single cell level.
    Analytical biochemistry, 2022, 12-15, Volume: 659

    Topics: Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Neoplasms; Oxidation-Reduction; Tryptophan

2022
L-Kynurenine participates in cancer immune evasion by downregulating hypoxic signaling in T lymphocytes.
    Oncoimmunology, 2023, Volume: 12, Issue:1

    Topics: Humans; Immune Evasion; Kynurenine; Neoplasms; Signal Transduction; T-Lymphocytes; Tumor Microenviro

2023
The role of cytokines and Indolamine-2.3 dioxygenase in experiencing a psycho-neurological symptom cluster in hematological cancer patients: IL-1alpha, IL-1beta, IL-4, IL-6, TNF-alpha, kynurenine, and tryptophan.
    Journal of psychosomatic research, 2023, Volume: 173

    Topics: Cytokines; Dioxygenases; Hematologic Neoplasms; Humans; Interleukin-4; Interleukin-6; Kynurenine; Ne

2023
IDO-triggered swellable polymeric micelles for IDO inhibition and targeted cancer immunotherapy.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 363

    Topics: Drug Delivery Systems; Humans; Immunotherapy; Kynurenine; Micelles; Neoplasms; Tryptophan; Tumor Mic

2023
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1.
    Nature immunology, 2023, Volume: 24, Issue:12

    Topics: Animals; Bias; Cell Differentiation; Core Binding Factor Alpha 2 Subunit; Erythroid Precursor Cells;

2023
Longitudinal associations of macronutrient and micronutrient intake with plasma kynurenines in colorectal cancer survivors up to 12 months posttreatment.
    The American journal of clinical nutrition, 2023, Volume: 118, Issue:5

    Topics: Eating; Humans; Kynurenic Acid; Kynurenine; Micronutrients; Neoplasms; Nutrients; Prospective Studie

2023
Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues.
    Methods in enzymology, 2019, Volume: 629

    Topics: Animals; Antibodies, Monoclonal; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluoresc

2019
Quantification of IDO1 enzyme activity in normal and malignant tissues.
    Methods in enzymology, 2019, Volume: 629

    Topics: Animals; Enzyme Assays; HeLa Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Mice;

2019
A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Cancer immunology, immunotherapy : CII, 2020, Volume: 69, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Screening As

2020
Simultaneous voltammetric analysis of tryptophan and kynurenine in culture medium from human cancer cells.
    Talanta, 2020, Mar-01, Volume: 209

    Topics: Biosensing Techniques; Boron; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressu

2020
Dual-functional conjugates improving cancer immunochemotherapy by inhibiting tubulin polymerization and indoleamine-2,3-dioxygenase.
    European journal of medicinal chemistry, 2020, Mar-01, Volume: 189

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Drug Design; Drug Scre

2020
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Cell; Cell Line

2020
Kynurenine pathway enzyme KMO in cancer progression: A tip of the Iceberg.
    EBioMedicine, 2020, Volume: 55

    Topics: Humans; Kynurenine; Neoplasms

2020
Computational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1.
    Aging, 2020, 06-22, Volume: 12, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Female;

2020
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
    Nature communications, 2020, 08-11, Volume: 11, Issue:1

    Topics: Animals; Drug Resistance, Neoplasm; Humans; Immune Tolerance; Immunotherapy; Indoleamine-Pyrrole 2,3

2020
Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
    Research in veterinary science, 2021, Volume: 137

    Topics: Animals; Cell Line, Tumor; Dog Diseases; Dogs; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynuren

2021
Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells.
    Nature communications, 2017, 05-10, Volume: 8

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Fem

2017
Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.
    SLAS discovery : advancing life sciences R & D, 2017, Volume: 22, Issue:10

    Topics: Animals; Cell Line, Tumor; Imaging, Three-Dimensional; Kynurenine; Mass Spectrometry; Mice; Neoplasm

2017
SBMLmod: a Python-based web application and web service for efficient data integration and model simulation.
    BMC bioinformatics, 2017, Jun-24, Volume: 18, Issue:1

    Topics: Cell Line, Tumor; Humans; Internet; Kynurenine; Models, Theoretical; Neoplasms; Serotonin; Tryptopha

2017
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
    Nature biotechnology, 2018, Volume: 36, Issue:8

    Topics: Adjuvants, Immunologic; Animals; Cancer Vaccines; Cell Line, Tumor; Humans; Hydrolases; Indoleamine-

2018
Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
    Bioanalysis, 2018, Aug-01, Volume: 10, Issue:16

    Topics: Animals; Biomarkers; Blood Chemical Analysis; Chromatography, Liquid; Indoleamine-Pyrrole 2,3,-Dioxy

2018
The metabolite BH4 controls T cell proliferation in autoimmunity and cancer.
    Nature, 2018, Volume: 563, Issue:7732

    Topics: Administration, Oral; Alcohol Oxidoreductases; Animals; Autoimmune Diseases; Biopterins; Cell Line,

2018
Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Journal of pharmaceutical and biomedical analysis, 2019, Jun-05, Volume: 170

    Topics: Animals; Chromatography, Liquid; Disease Models, Animal; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynur

2019
Impact of physical exercise on the kynurenine pathway in patients with cancer: current limitations and future perspectives.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:8

    Topics: Depression; Depressive Disorder; Exercise; Humans; Kynurenine; Neoplasms

2019
The landscape of cancer cell line metabolism.
    Nature medicine, 2019, Volume: 25, Issue:5

    Topics: Animals; Asparaginase; Asparagine; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Cell Lin

2019
Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study.
    Cancer, 2014, Nov-01, Volume: 120, Issue:21

    Topics: Adult; Aged; Biomarkers, Tumor; C-Reactive Protein; Female; Follow-Up Studies; Humans; Inflammation;

2014
Markers of vitamin B6 status and metabolism as predictors of incident cancer: the Hordaland Health Study.
    International journal of cancer, 2015, Jun-15, Volume: 136, Issue:12

    Topics: Aged; Biomarkers; Female; Follow-Up Studies; Health Surveys; Humans; Incidence; Kynurenine; Male; Mi

2015
An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Animals; Autocrine Communication; Cell Line, Tumor; Cytokines; Down-Regulation; Drug Resistance, Neo

2015
Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas.
    Chemical research in toxicology, 2016, 09-19, Volume: 29, Issue:9

    Topics: DNA Replication; Genomic Instability; Glioma; Humans; Kynurenine; Neoplasms; Signal Transduction

2016
Development of screen-printed tryptophan-kynurenine immunosensor for in vitro assay of kynurenine-mediated immunosuppression effect of cancer cells on activated T-cells.
    Biosensors & bioelectronics, 2017, Jun-15, Volume: 92

    Topics: Antibodies, Immobilized; Biosensing Techniques; Cell Line, Tumor; Electrodes; Equipment Design; Gold

2017
Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:2

    Topics: Amidines; Animals; Cell Line, Tumor; Dogs; Enzyme Inhibitors; Female; Humans; Immune System; Immunot

2010
Indoleamine 2,3-dioxygenase, Tregs and cancer.
    Current medicinal chemistry, 2011, Volume: 18, Issue:15

    Topics: Animals; Enzyme Inhibitors; Forkhead Transcription Factors; Humans; Immune Tolerance; Indoleamine-Py

2011
Evading immunity: new enzyme implicated in cancer.
    Journal of the National Cancer Institute, 2012, Mar-07, Volume: 104, Issue:5

    Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn

2012
Kynurenine in disease, with particular reference to cancer.
    Canadian Medical Association journal, 1955, Aug-01, Volume: 73, Issue:3

    Topics: Body Fluids; Kynurenine; Neoplasms; Urine

1955
[Certain metabolic peculiarities observed in individuals with tumors of the bladder; preventive note].
    Bollettino della Societa italiana di biologia sperimentale, 1958, Aug-31, Volume: 34, Issue:16

    Topics: Aminobenzoates; Humans; Kynurenine; Neoplasms; Urinary Bladder Neoplasms

1958
Metabolism of tryptophan in cancer of various sites.
    Annales medicinae experimentalis et biologiae Fenniae, 1963, Volume: 41

    Topics: Indoleacetic Acids; Kynurenine; Neoplasms; ortho-Aminobenzoates; Tryptophan; Xanthurenates

1963
PRELIMINARY STUDIES ON TRYPTOPHAN PYRROLASE ACTIVITY IN MICE.
    Annals of biochemistry and experimental medicine, 1963, Volume: 23

    Topics: Adenocarcinoma; Animals; Kynurenine; Liver; Mice; Neoplasms; Neoplasms, Experimental; Oxidation-Redu

1963
[BIOCHEMICAL STUDIES ON THE METABOLISM OF THE TUMOR BEARING ANIMALS. II. RESEARCHES FOR THE AMINO ACIDS IN THE URINE OF THE RATS FED ON THE DAB-RICE].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 1963, Volume: 83

    Topics: Amino Acids; Chromatography; Kynurenine; Liver Neoplasms; Neoplasms; Neoplasms, Experimental; p-Dime

1963
STUDIES ON THE TRYPTOPHAN METABOLISM IN TUMOR-BEARING ANIMALS.
    Gan, 1964, Volume: 55

    Topics: Animals; Kynurenic Acid; Kynurenine; Liver; Neoplasms; Neoplasms, Experimental; Niacin; Nicotinic Ac

1964
URINARY EXCRETION OF TRYPTOPHAN METABOLITES IN PATIENTS WITH RENAL PELVIS AND PARENCHYMA TUMOURS.
    Urologia internationalis, 1964, Volume: 17

    Topics: Chromatography; Humans; Kidney Neoplasms; Kidney Pelvis; Kynurenic Acid; Kynurenine; Neoplasms; orth

1964
MOUSE BLADDER CARCINOGENICITY OF CERTAIN TRYPTOPHAN METABOLITES AND OTHER AROMATIC NITROGEN COMPOUNDS SUSPENDED IN CHOLESTEROL.
    Cancer research, 1964, Volume: 24

    Topics: Amines; Animals; Carcinogens; Cholesterol; Fluorenes; Hydroxylamines; Kynurenic Acid; Kynurenine; Me

1964
STUDIES ON THE URINARY EXCRETION OF CERTAIN TRYPTOPHAN METABOLITES BEFORE AND AFTER TRYPTOPHAN LOADING DOSE IN BILHARZIASIS, BILHARZIAL BLADDER CANCER AND CERTAIN OTHER TYPES OF MALIGNANCIES IN EGYPT.
    British journal of cancer, 1964, Volume: 13

    Topics: Amino Acids; Egypt; Epidemiology; Fluids and Secretions; Humans; Hydroxyindoleacetic Acid; Indoleace

1964
Kynurenine accumulation in tumor-bearing mice.
    Acta - Unio Internationalis Contra Cancrum, 1960, Volume: 16

    Topics: Animals; Kynurenine; Mice; Neoplasms

1960
Diminished quality of life in patients with cancer correlates with tryptophan degradation.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:7

    Topics: Aged; Disease Progression; Fatigue; Female; Humans; Immunity, Cellular; Karnofsky Performance Status

2007
Studies on tryptophan metabolism in malignant tumor.
    Wakayama medical reports, 1967, Volume: 12, Issue:2

    Topics: Animals; Chromatography, Paper; Humans; Kynurenine; Mucoproteins; Neoplasms; Radiation Effects; Rats

1967
Inactivation of antiadherence effect of bladder surface glycosaminoglycans as possible mechanism for carcinogenesis.
    Urology, 1987, Volume: 30, Issue:3

    Topics: 3-Hydroxyanthranilic Acid; Animals; Bacterial Adhesion; Cyclamates; Glycosaminoglycans; Kynurenine;

1987
Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
    Cancer research, 1989, Sep-01, Volume: 49, Issue:17

    Topics: Biopterins; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Interleukin-2; Kynurenine; Ne

1989
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity.
    Journal of interferon research, 1986, Volume: 6, Issue:4

    Topics: Carcinoma; Cells, Cultured; Fibroblasts; Humans; Interferon beta-1a; Interferon beta-1b; Interferon

1986
The tryptophan load as a test for pyridoxine deficiency in hospitalized patients.
    Annals of the New York Academy of Sciences, 1969, Sep-30, Volume: 166, Issue:1

    Topics: Adult; Aged; Arteriosclerosis; Female; Gastrointestinal Diseases; Humans; Kynurenine; Male; Middle A

1969
[Tryptophan-pyrrolase activity in patients with neoplasms of various types].
    Bollettino della Societa italiana di biologia sperimentale, 1969, Apr-30, Volume: 45, Issue:8

    Topics: Humans; Kynurenine; Liver; Neoplasms; Tryptophan; Tryptophan Oxygenase

1969